Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines
Annals of Laboratory Medicine
; : 180-193, 2017.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-8638
Responsible library:
WPRO
ABSTRACT
Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
Neglected Diseases
/
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
Target 3.3: End transmission of communicable diseases
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Neglected Diseases
/
Tuberculosis
/
Tuberculosis
Database:
WPRIM (Western Pacific)
Main subject:
Arylamine N-Acetyltransferase
/
Pulmonary Embolism
/
Tuberculosis
/
Warfarin
/
Coronary Artery Disease
/
Ticlopidine
/
Laboratories, Hospital
/
Platelet Aggregation Inhibitors
/
Cytochrome P-450 CYP2D6
/
Depressive Disorder
Type of study:
Practice guideline
Language:
English
Journal:
Annals of Laboratory Medicine
Year:
2017
Document type:
Article